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proved to be efficacious in the management of SSTI. An economic evaluation was
performed to determine the most cost-effective alternative between daptomycin
and linezolid for the treatment of SSTI with failure to vancomycin therapy.
METHODS: A cost-effectiveness analysis was performed from an institutional per-
spective (Mexican Institute of Social Security, IMSS). Both drugs are includedwithin
the treatment guidelines as secondary therapy for SSTI following vancomycin fail-
ure. As required per guidelines, use of concomitant therapy with ciprofloxacin and
metronidazole was also considered. Effectiveness and safety data was taken from
published literature; effectiveness parameters included clinical and microbiologi-
cal cure, and safety parameters includeddrug-related adverse events. Resource use
data was obtained from the institution; total direct costs of hospitalization and
treatment were considered. The source of the unit costs was the institution, cur-
rent for 2010. All costs are expressed in local currency (Mexican Pesos, MXP). The
time horizon was less than 1 year; no discount rate was used. A decision tree was
built, considering two possible outcomes: success and failure to treatment. A prob-
abilistic sensitivity analysis was performed through aMonte Carlo simulationwith
100,000 iterations to confirm the robustness of the model. RESULTS: The results
show a cost/effectiveness ratio of $52,135.67 MXP for daptomycin compared to
$67,623.14 MXP for linezolid, making daptomycin a more cost-effective alternative
(dominant) for the treatment of SSTI. The sensitivity analysis confirmed the ro-
bustness of the model. CONCLUSIONS: From an institutional perspective in Mex-
ico, daptomycin is a more cost-effective (dominant) alternative than linezolid for
the treatment of SSTI in patients that failed treatment with vancomycin.
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COST EFFECTIVENESS ANALYSIS OF THE COMBINATION EFAVIRENZ (EFV),
TENOFOVIR (TDF) AND EMTRICITABINE (FTC) ONCE A DAY IN TREATMENT OF
NAÏVE ADULT PATIENTS WITH HIV INFECTION IN MEXICO
Rizzoli-Cordoba A1, Delgado-Ginebra I2, Pizarro-Castellanos M1, Castillo JJ3
1Hospital Infantil de México Federico Gómez, Mexico City, Mexico, 2Panamerican University,
México City, Mexico, 3IMSS, México City, Mexico
OBJECTIVES: To evaluate the cost effectiveness analysis of Efavirenz/Emtricit-
abine/Tenofovir ((TDFFTCEFV) in naïve patientswithHIV from the public health
system Mexican perspective. METHODS: A decision tree model was developed to
estimate the efficacy and expected value of direct medical costs. Efficacy wasmea-
sured by the percentage of individuals with plasma HIV RNA  50 copies/mL and
and 400 copies/mL. at 96 weeks, based on a systematic review andmeta-analysis
of clinical trials of regimens in treatment-naïve populations. Model follows the
recommendations of antiretroviral persons handling Guide with HIV in Mexico
(2009 SSA). The direct costs and treatment of adverse events in the treatment of
HIV were estimated. When the patient failure, the cost of new treatment was
added. The unitary costs were obtained from the Mexican public health institu-
tions. All costs were calculated in 2010 Mexican Pesos (MXP). Incremental-cost-
effectiveness-ratios were expressed as cost per 1% of individuals with plasma HIV
RNA  50 copies/mL and and  400 copies/mL Costs and outcomes were dis-
counted at 5%. Probabilistic sensitivity analyses via Monte Carlo simulations were
undertaken to incorporate likely distributional properties of key model. RESULTS:
EFVFTCTDF was most effective than others comparators with probability of
0.734 (CI95%:0.601-0.835; n514) -except when compare with TDF/FTC  ATV/r
with efficacy of 0.743 CI95%:0.700-0.786; n440- and 0.746 (0.686-0.798; n232) of
having 50 or 400 RNA copies/ml respectively at 96 weeks, EFVFTCTDF re-
sulted as the alternative with less unitary average total cost ($60,026.00 MX and
$60,122.00, respectively). TDF/FTC/EFV combination is a dominant option and cost
saving compared to alternatives, except TDF/FTC  ATV/r (cost per 1% of individ-
uals with plasma HIV RNA  50 copies/mL of $8,490,581).Deterministic and prob-
abilistic sensitivity analysis showed that the findings are robust. CONCLUSIONS:
Efavirenz/Emtricitabine/Tenofovir is a cost effective drug on 96weeks for the treat-
ment of adult naïve patients with HIV infection in Mexico.
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DIAGNOSIS AND TREATMENT OF INFLUENZA-LIKE ILLNESS IN HEALTHY
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OBJECTIVES: This study predicted and analyzed outcomes among six options (uni-
versal antiviral therapy without testing [Universal], empiric therapy without test-
ing [Empiric], empiric therapy with lab testing [Empiric_Lab], treatments respond-
ing to lab results [Standard], treatments responding to point-of-care testing [POCT]
results and no treatment [NoTx]) in healthy adults with influenza-like symptoms
who visit physicians within or beyond 48 hours of the onset of symptoms.
METHODS: A decision model was created to predict total and direct medical costs,
symptom-free days, quality of life and days of work lost within 14 days from the
perspective of patients. Most model inputs were derived from the literature; some
were obtained from internal data and expert opinions. Total costs (in $2009 USD)
included costs associated with prescriptions/OTC, tests, complications, hospital-
ization and work-day loss. Cost-effectiveness analysis, cost-utility analysis and
probabilistic sensitivity analysis were performed. RESULTS: Total costs per symp-
tom-free day were $119 ($874/7.3), $130 ($893/6.9), $163 ($1,086/6.7), $162 ($1,103/
6.8), $189 ($1,117/5.9) and $280 ($1117/4.2) for Universal, NoTx, Standard, POCT,
Emiric_Lab and Empiric, respectively. Total costs per quality of lifewere $1,560 ($874/
0.56), $1,641 ($893/0.54), $2,156 ($1,086/0.50), $1,949 ($1,103/0.57), $1,993 ($1,117/0.56)
and $2,195 ($1117/0.54) for Universal, NoTx, Standard, POCT, Emiric_Lab and Empiric,
respectively. Direct medical costs were $238, $169, $380, $336, $358 and $193 for Uni-
versal, NoTx, Standard, POCT, Emiric_Lab and Empiric, respectively. Direct medical
costs per symptom-free daywere $46, $25, $57, $49, $60 and $$46 for Universal, NoTx,
Standard, POCT, Emiric_LabandEmpiric, respectively.Directmedical costsperquality
of lifewere $425, $311, $755, $594, $639and$$360 forUniversal,NoTx, Standard, POCT,
Emiric_Lab and Empiric, respectively. Sensitivity analysis indicated the study results
were robust.CONCLUSIONS:With consideration of total costs, the universal option
was themost cost-effective option.With consideration of directmedical costs only,
no treatment is the most cost-effective option.
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OBJECTIVES:Antiretroviral combinations have been successful in delaying human
immunodeficiency virus (HIV) progression; however, drug resistance may occur.
Maraviroc and enfuvirtide are two drugs currently used in treatment-experienced
HIV patients. The objective was to determine the economic impact of maraviroc
versus enfuvirtide in HIV patients previously treated with conventional
antiretrovirals.METHODS:AMarkovmodelwas developed to assess the economic
consequences of the targeted therapies. The type of analysis was cost-minimiza-
tion based on the premise of clinical equivalence. The clinical outcome used to
support the clinical assumption was the odds ratio of decreasing1.0 log10 viral
copies/ml over placebo. Targeted populationwas composed of adults infectedwith
HIV virus (CCR5 co-receptor tropism), who underwent previous anti-HIV treat-
ments and proved therapeutic failure. Model input data derived from a previously
observed cohort of HIV patients in Brazil. A lifetime horizon was used. The eco-
nomic perspectivewas that of the BrazilianMinistry of Health (MoH) as a payer and
provider of medical services, treatments, and healthcare to its beneficiaries. Costs
were expressed in 2010 Brazilian Currency (1BRL0.59USD). Univariate and multi-
variate (Monte Carlo) analyses tested model robustness. RESULTS: An indirect
comparison between the interventions showed that the effects of the drugs over
placebo was similar from a clinical (odds ratios with approximate values) and
statistical (overlapping confidence intervals) standpoints. Thus, clinical equiva-
lence between the drugs was assumed. The economic analysis showed that the
total cost of anti-HIV treatment per patient with maraviroc was approximately
BRL17 thousand lower than enfuvirtide. Probabilistic sensitivity analysis reported
87% chance of having reduced treatment costs by choosing maraviroc over
enfuvirtide. CONCLUSIONS: The use of maraviroc in treatment-experienced HIV
patients showed to be beneficial for the Brazilian MoH in reducing the economic
burden of the disease. The estimated annual budget impact ranged between BRL
8.0 to 10.5 million favorable to cost reduction.
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OBJECTIVES:Raltegravir, an integrase inhibitor ofHIV-1, is approved for use in both
treatment naïve and treatment experienced HIV-1 infected patients. In Sweden,
raltegravir is reimbursed for patients with documented drug resistance and used
predominately in heavily treated experienced patients. This study aims to inves-
tigate the cost-effectiveness of using raltegravir in treatment naïve patients versus
using raltegravir as a salvage treatment.METHODS:A three-stage continuous-time
Markovmodel representing successive HIV therapies was developed to predict the
costs and quality-adjusted life years (QALYs) over a 50-year time horizon. Patients
progressed to the next stage in themodel as they failed or discontinued the current
therapy for toxicity reasons. In each stage patientsmoved between 18 health states
based on CD4 and HIV RNA levels. At anytime patients could die, suffer coronary
heart disease or develop acquired immunodeficiency syndrome (AIDS). Initiation
on a raltegravir-based regimen was evaluated versus initiation on a protease in-
hibitor (PI)-based regimen. During the second stage patients received a non-nucle-
oside reverse transcriptase inhibitor based regimen. Patients initiating on raltegra-
vir progressing to the third stage received optimized salvage therapy (OT) whereas
patients initiating on a PI received OT plus raltegravir. Data on effectiveness was
gathered from randomized clinical trials and an HIV/AIDS database. Utilities and
health care resource usewere gathered from the literature and adapted to Swedish
situation using expert opinion. RESULTS: Raltegravir-initiating treatment strategy
offered longer undiscounted life expectancy compared to PI initiating strategy
[20.51 vs. 18.60 years]. The incremental cost-utility ratio for using raltegravir in
treatment naïve patients versus using raltegravir as a salvage treatmentwas 85 182
SEK per QALY ($12,564/QALY). Results were sensitive to analytical time horizon.
CONCLUSIONS: Given the data and methods used, the model suggests that using
raltegravir in treatment naïve patients compared to using raltegravir as a salvage
therapy is cost-effective.
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OBJECTIVES: Although influenza affects all age groups, influenza is common in
children. Between 15% and 42% of preschool and school-aged children experience
influenza each season. Recently, LAIV has been approved in Canada for use in
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eligible persons aged 2-59 years of age. The study objectives were to determine the
cost-effectiveness of LAIV compared to TIV in Canadian children and adolescents
from aMinistry of Health (MoH) perspective and a societal perspective.METHODS:
A previously published US cost-effectiveness model using patient-level data to
compare LAIV and TIV was supplemented by secondary (e.g. literature) and pri-
mary data (i.e. survey of 144 Canadian physicians). To compare the costs and ben-
efits of LAIV and TIV, a cost-utility analysis was conducted. Parameter uncertainty
was addressed through probability sensitivity analysis (PSA). RESULTS: Although
LAIV increased vaccination costs compared to TIV, LAIV reduced the number of
influenza illness cases and lowered the number of hospitalizations, ER visits, out-
patient visits andparents’ days lost fromwork. The estimated offsets in direct costs
savedwere $4.19 per vaccinated child aged 2-17 years. Societal savings were $35.33
per vaccinated child. When costs and outcomes were considered, LAIV was the
dominant strategy when compared to TIV. At a willingness to pay of $50,000 per
QALY gained, the results of the PSA indicated that the probability of LAIV being
cost-effective was almost 1. CONCLUSIONS: LAIV reduces the burden of influenza
in children and adolescents. Consistent with US results, vaccinating children with
LAIV instead of TIV is the dominant strategy from a societal and MoH perspective.
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OBJECTIVES: To estimate the long-term costs and effectiveness of entecavir com-
pared with lamivudine and adefovir in treating chronic HBeAg-positive infection.
METHODS:We compare key outcomes related to survival, costs, and QOL for HBV
patients. A lifetime Markov model was used to estimate the expected outcomes
and costs for HBV patients treated with entecavir vs lamivudine and adefovir. The
impact of treatingHBVwith entecavir, lamivudine and adefovir in patientswho are
positive for hepatitis B e antigen (HBeAg) was based on the efficacy and safety
results of the Phase 3, double-blind, randomized controlled trial. Utility values
were derived from published literature. The cost-effective analysis was conducted
from the Mexican Healthcare perspective. Costs were derived from the literature
and expert interviews, future costs and effects were discounted at 5% per recom-
mendations for analyses in Mexico. All costs are presented in 2010 US dollars.
Multiple 1-way sensitivity analyses were performed to address uncertainty.
RESULTS: The model projects an accumulated discounted cost to the Mexican
healthcare systemper patient receiving the entecavir regimen of $28,356 compared
to $28,325 for adefovir and $27,901 for lamivudine regimen. The base-case analysis
presented incremental cost-effectiveness ratios for entecavir vs adefovir and lami-
vudine of $123 per QALY and $ 1,574 per QALY respectively. These values are in
accordance with the recommendations of the Commission on Macroeconomics
and Health, WHO, suggesting that health technologies with ICERs below the per
capita GDP are considered very cost-effective. Results were robust to various as-
sumptions tested in the sensitivity analysis. CONCLUSIONS: Results from this
study analyses suggest that in the Mexican setting, use of entecavir in place of
adefovir and lamivudine for treatment of HBV is likely to be cost effective. These
conclusions are supported by conservative assumptions and sensitivity analysis.
Infection – Patient-Reported Outcomes & Preference-Based Studies
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OBJECTIVES: Community pharmacies focused on HIV offer enhanced services to
assist patients taking antiretrovirals (ARV), yet the impact of these services is un-
clear. The objective of this study was to determine differences in patient charac-
teristics, regimen characteristics, and regimen refill adherence for HIV-SP versus
NSP users. METHODS: We conducted a retrospective database study of patients
with ARV claims fromMay 2007 – August 2009 at CaliforniaWalgreens pharmacies.
A modified medication possession ratio (mMPR) was used to calculate regimen
refill adherence. Patients were deemed “regimen adherent” on any given study day
if they possessed three or more antiretroviral drugs that included: a protease in-
hibitor, a non-nucleoside reverse transcriptase inhibitor, raltegravir, an entry in-
hibitor, abacavir, or tenofovir. A patient’s regimen adherent days were summed,
then divided by the total number of study days contributed to calculate themMPR.
A multivariable logistic regression model was constructed to determine indepen-
dent factors which contributed to having  95% regimen refill adherence.
RESULTS: 4254 HIV-SP and 11679NSP userswere included. Compared to NSP users,
HIV-SP users traveled farther to their pharmacies (5.03 vs. 1.26 miles), filled more
chronic disease medications (35% vs. 30%) and psychotropics (42% vs. 39%), and
received more fixed dose combination (FDC) ARVs (92% vs. 83%;); all p  0.01.
Median regimenmMPRwas higher for HIV-SP users (90% vs. 77%, p 0.0001). After
adjustment for various factors, both the use of HIV-SP (OR 1.79, 95% CI 1.72-2.08)
and fixed dose combination ARV tablets (OR3.3, 95% CI 2.86-4.01) were associated
with a greater likelihood of having95% regimen refill adherence. CONCLUSIONS:
Patients filling their prescriptions at HIV-SP are more likely to use fixed dose com-
bination ARV and have higher regimen refill adherence; particularly those taking
FDCs. HIV-SP should be further explored to determine whether specific services
improve patient adherence.
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OBJECTIVES: Immunization dosewas considered as amissed immunization dose if
pediatric didn’t receive at least one immunization dose. The aims of this study are
to determine the frequency and percent of missed doses among pediatric immu-
nization schedule, to determine the number of immunization doses missed by
each child, and to evaluate the correlation between missed dose frequency and
parent’s knowledge.METHODS: Data was collected retrospectively from 528 pedi-
atric immunization cards in Iraq to obtain the immunization history of each indi-
vidual child. This study was restricted the analyses to the vaccines administered
before age of 2 years. Each pediatric must received seven doses at seven different
times, every dose consist of many types of vaccines. Validated questionnaire was
used to measure immunization parent’s knowledge and Spearman rho correlation
test was used to evaluate the correlation between missed dose frequency and
parent’s knowledge. RESULTS:More than 30% ofmissed immunization doses were
shown in the seventh or last dose (OPVDTP) at 18 months of age. The majority of
pediatrics (54.1%) was immunized without any missed immunization dose out of
seven immunization doses. Four pediatrics (0.8%) were only having six missed
immunization doses. Missed immunization dose found to be negatively correlated
with knowledge score (correlation 0.263, P-value0.001). CONCLUSIONS: This
study suggests that compliancewithWHO immunization recommendations is low
and inappropriate immunization doses were occurred frequently, and leading to
incomplete or partial immunization compliance. With an increase in parent’s
knowledge of immunization guidelines against infectious agents, it is very impor-
tant to implement strategies that will lead to improved and developed immuniza-
tion practice and childhood immunization coverage in the future.
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OBJECTIVES: Immunization dosewas considered as a right immunization dose if it
was administered at the recommended age. The aims of this study are to deter-
mine the frequency and percent of this type of doses among pediatric immuniza-
tion schedule, to determine the number of right immunization dose received by
each child, and to evaluate the correlation between right dose frequency and par-
ent’s knowledge.METHODS: Data was collected retrospectively from 528 pediatric
immunization cards in Iraq to obtain the immunization history of each individual
child. This study was restricted the analyses to the vaccines administered before
age 2 years. Each pediatric must received seven doses at seven times, every dose
consist of many types of vaccines. Validated questionnaire was used to measure
immunization parent’s knowledge and Spearman rho correlation test was used to
evaluate the correlation between right doses frequency and parent’s knowledge.
RESULTS:More than 45% of right immunization doses were shown in the first dose
(BCGOPVHEP B.) at first week of pediatric life. The majority of pediatric (28%)
were immunized with one right immunization dose out of seven immunization
doses. Four pediatric (0.8%) were only immunized with seven normal immuniza-
tion doses, while 132 pediatric (25%) were immunized without any dose as right
immunization dose. Right immunization dose found to be positively correlated
with knowledge score (correlation 0.358, P-value0.001). CONCLUSIONS: This
study found that compliance with WHO immunization recommendations is low
and inappropriate immunization doses were occur frequently, and leading to in-
complete or partial immunization compliance.With an increase in parent’s knowl-
edge of immunization guidelines against infectious agents, it is very important to
implement strategies that will lead to improved and developed immunization
practice and childhood immunization coverage in the future.
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OBJECTIVES: Vaccine barriers addressed in this study were included lack of edu-
cation, lack of funding, lack of vaccine availability, lack of medical facilities, and
fear of a side effect. The aims of this study are to determine immunization barriers
and to evaluate the solutions suggested by parents. METHODS: A cross sectional
prospective surveywas carried out among 528 Iraqis parentswith child had improper
immunization schedule to obtaineddemographic data of immunized children. Trans-
lated and validated questionnaire were administered to parents, it consisted of mul-
tiple choice questions. The questions were related to the immunization barriers and
how to decrease this barrier? RESULTS:More than 90% of pediatrics have improper
immunization schedule with immunization doses errors. The majority of parents
perceived that the lack of vaccine availabilitywas themost common immunization
barrier (51.5%), and more than 42% of parents perceived that the lack of education
was the important barrier, while 88.4% of parents were thought that the lack of
founding wasn’t important immunization barrier. More than 60% of parents sug-
gested increasing immunization programs in the media to promote pediatrics im-
munization, and 44.7% of parents suggested increasing mother’s education to pro-
mote immunization. But 77.5% of parents thought that any increase in fundingwill
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